RU97105593A - VACCINE FOR PREVENTION OF ABDOMINAL TYPE - Google Patents

VACCINE FOR PREVENTION OF ABDOMINAL TYPE

Info

Publication number
RU97105593A
RU97105593A RU97105593/14A RU97105593A RU97105593A RU 97105593 A RU97105593 A RU 97105593A RU 97105593/14 A RU97105593/14 A RU 97105593/14A RU 97105593 A RU97105593 A RU 97105593A RU 97105593 A RU97105593 A RU 97105593A
Authority
RU
Russia
Prior art keywords
sodium
prevention
antigen
vaccine
phenol
Prior art date
Application number
RU97105593/14A
Other languages
Russian (ru)
Other versions
RU2111012C1 (en
Inventor
В.Л. Львов
П.Г. Апарин
Н.П. Ванеева
С.И. Елкина
Original Assignee
В.Л. Львов
П.Г. Апарин
Н.П. Ванеева
С.И. Елкина
Filing date
Publication date
Application filed by В.Л. Львов, П.Г. Апарин, Н.П. Ванеева, С.И. Елкина filed Critical В.Л. Львов
Priority to RU97105593A priority Critical patent/RU2111012C1/en
Priority claimed from RU97105593A external-priority patent/RU2111012C1/en
Application granted granted Critical
Publication of RU2111012C1 publication Critical patent/RU2111012C1/en
Publication of RU97105593A publication Critical patent/RU97105593A/en

Links

Claims (1)

Вакцинный препарат для профилактики брюшного тифа на основе физиологического раствора капсулярного Ви-антигена, выделенного из Salmonella typhi, содержащий вспомогательные вещества, отличающийся тем, что препарат содержит антиген, дополнительно обработанный дезокси- и рибонуклеазой, затем проназой и очищенный гель фильтрацией, а в качестве вспомогательных веществ содержит гидрортофосфат и дигидроортофосфат натрия и фенол при следующем соотношении компонентов, мас.%:
Ви-антиген - 0,004-0,006
Гидроортофосфат натрия - 0,01-0,02
Дигидроортофосфат натрия - 1,75-1,85
Хлорид натрия - 0,84-0,90
Фенол - 0,10-0,15
Вода дистиллированная - До 100A vaccine preparation for the prevention of typhoid fever based on a physiological solution of capsular Vi antigen isolated from Salmonella typhi containing excipients, characterized in that the preparation contains antigen additionally treated with deoxy and ribonuclease, then pronase and purified gel by filtration, and as auxiliary substances contains hydrofluorophosphate and sodium dihydroorthophosphate and phenol in the following ratio of components, wt.%:
Vi antigen - 0.004-0.006
Sodium hydroorthophosphate - 0.01-0.02
Sodium dihydroorthophosphate - 1.75-1.85
Sodium Chloride - 0.84-0.90
Phenol - 0.10-0.15
Distilled water - Up to 100
RU97105593A 1997-04-15 1997-04-15 Vaccine preparation for typhoid fever prophylaxis RU2111012C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU97105593A RU2111012C1 (en) 1997-04-15 1997-04-15 Vaccine preparation for typhoid fever prophylaxis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU97105593A RU2111012C1 (en) 1997-04-15 1997-04-15 Vaccine preparation for typhoid fever prophylaxis

Publications (2)

Publication Number Publication Date
RU2111012C1 RU2111012C1 (en) 1998-05-20
RU97105593A true RU97105593A (en) 1999-01-27

Family

ID=20191731

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97105593A RU2111012C1 (en) 1997-04-15 1997-04-15 Vaccine preparation for typhoid fever prophylaxis

Country Status (1)

Country Link
RU (1) RU2111012C1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE240118T1 (en) * 1998-08-28 2003-05-15 Glaxosmithkline Biolog Sa SALMONELLA TYPHI VACCINE COMPOSITIONS
WO2012154072A1 (en) * 2011-05-06 2012-11-15 Aparin Petr Gennadievich Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same

Similar Documents

Publication Publication Date Title
RU95108231A (en) Glp-1-molecular complex, pharmaceutical composition and method of complex preparing
BR9907995A (en) Immunological methods to modulate myostatin in vertebrate subjects
RU95122391A (en) ADJUVENTS FOR VACCINE AGAINST RESPIRATORY-SYNCITIAL VIRUS
HK1021738A1 (en) Purine l-nucleosides, analogs and uses thereof.
GB2255093A (en) Hiv-1 core protein fragments
EA200100127A1 (en) Phenylxanthine Derivatives
RU92016463A (en) APPLICATION OF DERIVATIVES OF TISSTINES FOR THE MANUFACTURE OF MEDICINES WITH IMMUNOMODING EFFECT, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS
DE69010301T2 (en) Use of L-sugar to make a laxative.
ATE90339T1 (en) BASIC SUBSTITUTED PHENYLACETONITRILES, THEIR PREPARATION AND MEDICATIONS CONTAINING THEM.
RU97105593A (en) VACCINE FOR PREVENTION OF ABDOMINAL TYPE
AR229486A1 (en) PROCEDURE FOR THE PREPARATION OF ADMINISTRABLE IMMUNOGLOBULIN BY INTRAVENOUS VIA TO STRENGTHEN THE IMMUNE DEFENSE OF THE HUMAN ORGANISM
DE69002946D1 (en) MEDICINE PREPARATION CONTAINING PARACETAMOL.
DE3012204A1 (en) ANTIGEN, PROCESS FOR ITS PRODUCTION AND ITS USE
Friedman Induction of immune response to protein antigens by subcutaneous co-injection with water-miscible vitamin A derivatives
Burnett et al. Coelenterate venom research 1991–1995: clinical, chemical and immunological aspects
Bertók Stimulation of nonspecific resistance by radiation-detoxified endotoxin
MX9206139A (en) (S) (+) -4-4 '- (1 METHYL-1,2-ETHANODIYL) -BIS (2,6-PIPERAZINDIONA) FORMULATIONS.
RU96124743A (en) OPHTHALMIC MEDICINE
SU1727820A1 (en) Method for stimulation of spermatogenesis in bulls
RU94026978A (en) IMMUNOTHERAPEUTIC DRUG
RU95114631A (en) MEANS FOR TREATING DISEASES COLI-INFECTED
RU95118869A (en) COMPOSITION OF GELATIN MASSES FOR PRODUCING CAPSULES
Browde et al. The use of modified total lymphoid irradiation in achieving transplantation tolerance in the primate
Shrestha TITANIUM TETRAFLUORIDE IN THE PREVENTION OF DENTAL CARIES: EFFECTS OF SYSTEMICALLY ADMINISTERED TITANIUM TETRAFLUORIDE ON RAT CARIES.
Khan Practical aspects of the treatment of hookworm infection in Kampala children